Figure 1. Discounted life-years and costs per person for all strategies in the base case.

When comparing 2 strategies, the one toward the right of the graph is more effective and the one toward the top of the graph is more costly. Tumor-testing strategies were more effective and more costly than clinical criteria strategies. The slope between 2 strategies represents the incremental cost-effectiveness ratio, with steeper slopes reflecting higher costs per life-year gained. The referent strategy reflects no active effort to diagnose the Lynch syndrome. IHC = immunohistochemistry; MSI = microsatellite instability.